PDCD1 and cancer: There are now several LAG3 modulators at various stages of preclinical and clinical development for the treatment of relapsed or refractory hematologic malignancies (NCT02061761), and advanced cancers, alone or in combination with anti-PD1 in patients with (NCT02966548, NCT03005782).